Article
Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis.
Future oncology (London, England) - 1 Aug 2020
Feinberg Bruce, Halmos Balazs, Gucalp Rasim, Tang Wenbo, Moehring Barbara, Hochmair Maximillian J
Abstract excerpt
Aim: To assess time-to-treatment failure (TTF) in US patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib-osimertinib treatment in the global, observational GioTag study. Patients & methods: Patients had EGFR T790M mutation-positive disease after first-line afatinib and subsequently received osimertinib. The primary outcome was TTF. Results: In 129 patients at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.